|Eligible Active Ingredient:
||Topical Clindamycin. As a topical preparation not exceeding 1%
|With Effective From:
||Treatment of acne vulgaris
|Maximum Daily Dose:
||Apply to the affected areas twice daily*
*Once daily for fixed combination products containing topical clindamycin not exceeding 1% and benzoyl peroxide
|Maximum Supply per Transaction:
||30g for gel;30ml for topical solution/lotion
|Minimum Age of User:
|Patient Information Leaflet from HSA/PSS:
||Download PIL (Link to HSA website)
Mechanism of Action of Topical Clindamycin
Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
Additional Information of Topical Clindamycin
||Anti-Acne Preparations For Topical Use
||Antiinfectives For Treatment Of Acne
||7-CDL | 7(S)-Chloro-7-deoxylincomycin | Cleocin (tn) | Clindamicina | Clindamycin | Clindamycine | Clindamycinum | Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
Show All HSA-registered therapeutic products granted exemption to supply without prescription
- Health Science Authority of Singapore – Reclassified POM
HSA-Registered Products Containing Topical Clindamycin As a topical preparation not exceeding 1%
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.